Roche Holdings AG (OTC:RHHBY) announced on Tuesday that it will invest $50 billion in the U.S. over the next five years.
These investments further strengthen Roche's already significant U.S. footprint, which includes 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions.
The investment is expected to create over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.
Also Read: Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
As part of this investment, Roche will increase its footprint of more than 25,000 employees in 24 sites across eight U.S. states. The investment will include:
- Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California.
- Gene therapy manufacturing facility in Pennsylvania.
- A new 900,000-square-foot manufacturing center to support Roche's expanding portfolio of next-generation weight loss medicines. The company says the location will be announced.
- A new manufacturing facility for continuous glucose monitoring in Indiana.
- A new R&D center in Massachusetts for conducting artificial intelligence research and as a hub for new cardiovascular, renal, and metabolism R&D efforts.
- Significant expansion and upgrading of existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana, and California.
Once all new and expanded manufacturing capacity comes online, Roche will export more medicines from the U.S. than it imports. The company says its diagnostics division already has an export surplus from the U.S. to other countries.
Earlier this month, Novartis AG (NYSE:NVS) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. over the next five years.
The move is part of a broader strategy to ensure that all key Novartis medicines for U.S. patients are produced domestically.
Earlier this year, Johnson & Johnson (NYSE:JNJ) announced its plans to invest more than $55 billion in the U.S. over the next four years, while Eli Lilly And Co (NYSE:LLY) plans to double its U.S. drug manufacturing spending from $23 billion to $50 billion within five years.
Read Next:
Photo: Gorodenkoff/Shutterstock